Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer

NARecruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
Non-small Cell Lung CancerMinimal Residual DiseaseAdaptive Treatment
Interventions
OTHER

Adaptive postoperative management based on minimal residual disease

participants will not receive postoperative treatment if (neoadjuvant therapy efficacy reaches pCR and) MRD results keep negative.

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Peking University

OTHER

collaborator

Guangdong Provincial People's Hospital

OTHER

collaborator

Jiangsu Cancer Institute & Hospital

OTHER

collaborator

Shanghai Chest Hospital

OTHER

collaborator

Shandong Cancer Hospital and Institute

OTHER

collaborator

Shenzhen Third People's Hospital

OTHER

collaborator

Second Xiangya Hospital of Central South University

OTHER

collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Peking University First Hospital

OTHER

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

National Institute for Occupational Safety and Health (NIOSH/CDC)

FED

lead

Peking University People's Hospital

OTHER